IDEAS home Printed from https://ideas.repec.org/r/sae/medema/v28y2008i5p713-722.html
   My bibliography  Save this item

The Role of Value for Money in Public Insurance Coverage Decisions for Drugs in Australia: A Retrospective Analysis 1994-2004

Citations

Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
as


Cited by:

  1. Ties Hoomans & Johan Severens & Nicole Roer & Gepke Delwel, 2012. "Methodological Quality of Economic Evaluations of New Pharmaceuticals in the Netherlands," PharmacoEconomics, Springer, vol. 30(3), pages 219-227, March.
  2. Whitty, Jennifer A. & Littlejohns, Peter, 2015. "Social values and health priority setting in Australia: An analysis applied to the context of health technology assessment," Health Policy, Elsevier, vol. 119(2), pages 127-136.
  3. Gu, Yuanyuan & Lancsar, Emily & Ghijben, Peter & Butler, James RG & Donaldson, Cam, 2015. "Attributes and weights in health care priority setting: A systematic review of what counts and to what extent," Social Science & Medicine, Elsevier, vol. 146(C), pages 41-52.
  4. Kanavos, Panos & Visintin, Erica & Gentilini, Arianna, 2023. "Algorithms and heuristics of health technology assessments: A retrospective analysis of factors associated with HTA outcomes for new drugs across seven OECD countries," Social Science & Medicine, Elsevier, vol. 331(C).
  5. Bae, Green & Bae, Eun Young & Bae, SeungJin, 2015. "Same drugs, valued differently? Comparing comparators and methods used in reimbursement recommendations in Australia, Canada, and Korea," Health Policy, Elsevier, vol. 119(5), pages 577-587.
  6. Fischer, Katharina E. & Rogowski, Wolf H. & Leidl, Reiner & Stollenwerk, Björn, 2013. "Transparency vs. closed-door policy: Do process characteristics have an impact on the outcomes of coverage decisions? A statistical analysis," Health Policy, Elsevier, vol. 112(3), pages 187-196.
  7. Constanza Vargas & Rebecca Addo & Milena Lewandowska & Philip Haywood & Richard Abreu Lourenco & Stephen Goodall, 2024. "Use of Health Technology Assessment for the Continued Funding of Health Technologies: The Case of Immunoglobulins for the Management of Multifocal Motor Neuropathy," Applied Health Economics and Health Policy, Springer, vol. 22(1), pages 73-84, January.
  8. Mauskopf, Josephine & Chirila, Costel & Birt, Julie & Boye, Kristina S. & Bowman, Lee, 2013. "Drug reimbursement recommendations by the National Institute for Health and Clinical Excellence: Have they impacted the National Health Service budget?," Health Policy, Elsevier, vol. 110(1), pages 49-59.
  9. Néboa Zozaya & Javier Villaseca & Irene Fernández & Fernando Abdalla & Benito Cadenas-Noreña & Miguel Ángel Calleja & Pedro Gómez-Pajuelo & Jorge Mestre-Ferrándiz & Juan Oliva-Moreno & José Luis Trill, 2024. "A Review of Current Approaches to Evaluating and Reimbursing New Medicines in a Subset of OECD Countries," Applied Health Economics and Health Policy, Springer, vol. 22(3), pages 297-313, May.
  10. Helen Dakin & Nancy Devlin & Yan Feng & Nigel Rice & Phill O'Neill & David Parkin, 2015. "The Influence of Cost‐Effectiveness and Other Factors on Nice Decisions," Health Economics, John Wiley & Sons, Ltd., vol. 24(10), pages 1256-1271, October.
  11. Paul R. Healey & Dominic Tilden & Dan Jackson & Lara Aghajanian, 2022. "A Cost-Utility Analysis of Trabecular Bypass Devices Versus Usual Care for Patients With Open-Angle Glaucoma," PharmacoEconomics - Open, Springer, vol. 6(3), pages 355-365, May.
  12. Lesley Chim & Patrick Kelly & Glenn Salkeld & Martin Stockler, 2010. "Are Cancer Drugs Less Likely to be Recommended for Listing by the Pharmaceutical Benefits Advisory Committee in Australia?," PharmacoEconomics, Springer, vol. 28(6), pages 463-475, June.
  13. Jennifer A Whitty & Ruth Walker & Xanthe Golenko & Julie Ratcliffe, 2014. "A Think Aloud Study Comparing the Validity and Acceptability of Discrete Choice and Best Worst Scaling Methods," PLOS ONE, Public Library of Science, vol. 9(4), pages 1-9, April.
  14. Jing Jing Li & Anthony Harris, 2025. "Dynamic Bargaining Over Public Insurance Coverage For Drugs In Australia," Papers 2025-09, Centre for Health Economics, Monash University.
  15. Kisser, Agnes & Tüchler, Heinz & Erdös, Judit & Wild, Claudia, 2016. "Factors influencing coverage decisions on medical devices: A retrospective analysis of 78 medical device appraisals for the Austrian hospital benefit catalogue 2008–2015," Health Policy, Elsevier, vol. 120(8), pages 903-912.
  16. Malinowski, Krzysztof Piotr & Kawalec, Paweł & Trąbka, Wojciech, 2016. "Impact of patient outcomes and cost aspects on reimbursement recommendations in Poland in 2012–2014," Health Policy, Elsevier, vol. 120(11), pages 1249-1255.
  17. Amarzaya Jadambaa & Nicholas Graves & Donna Cross & Rosana Pacella & Hannah J. Thomas & James G. Scott & Qinglu Cheng & David Brain, 2022. "Economic Evaluation of an Intervention Designed to Reduce Bullying in Australian Schools," Applied Health Economics and Health Policy, Springer, vol. 20(1), pages 79-89, January.
  18. Lesley Chim & Glenn Salkeld & Patrick Kelly & Wendy Lipworth & Dyfrig A Hughes & Martin R Stockler, 2017. "Societal perspective on access to publicly subsidised medicines: A cross sectional survey of 3080 adults in Australia," PLOS ONE, Public Library of Science, vol. 12(3), pages 1-24, March.
  19. Angela Rocchi & Elizabeth Miller & Robert Hopkins & Ron Goeree, 2012. "Common Drug Review Recommendations," PharmacoEconomics, Springer, vol. 30(3), pages 229-246, March.
  20. Fischer, Katharina Elisabeth, 2012. "A systematic review of coverage decision-making on health technologies—Evidence from the real world," Health Policy, Elsevier, vol. 107(2), pages 218-230.
  21. Anita Lal & Mohammadreza Mohebi & Kerryann Wyatt & Ayesha Ghosh & Kate Broun & Lan Gao & Nikki McCaffrey, 2024. "Tailored recruitment interventions to improve bowel cancer screening in Arabic and Mandarin speaking groups: Modelled cost-effectiveness," PLOS ONE, Public Library of Science, vol. 19(11), pages 1-17, November.
  22. Rashidul Alam Mahumud & Khorshed Alam & Jeff Dunn & Jeff Gow, 2019. "The cost-effectiveness of controlling cervical cancer using a new 9-valent human papillomavirus vaccine among school-aged girls in Australia," PLOS ONE, Public Library of Science, vol. 14(10), pages 1-18, October.
  23. Jennifer Whitty & Paul Scuffham & Sharyn Rundle-Thielee, 2011. "Public and decision maker stated preferences for pharmaceutical subsidy decisions," Applied Health Economics and Health Policy, Springer, vol. 9(2), pages 73-79, March.
  24. Peter Ghijben & Yuanyuan Gu & Emily Lancsar & Silva Zavarsek, 2018. "Revealed and Stated Preferences of Decision Makers for Priority Setting in Health Technology Assessment: A Systematic Review," PharmacoEconomics, Springer, vol. 36(3), pages 323-340, March.
  25. Pierluigi Russo & Matteo Zanuzzi & Angelica Carletto & Annalisa Sammarco & Federica Romano & Andrea Manca, 2023. "Role of Economic Evaluations on Pricing of Medicines Reimbursed by the Italian National Health Service," PharmacoEconomics, Springer, vol. 41(1), pages 107-117, January.
  26. Laura Vallejo-Torres & Borja García-Lorenzo & Laura Catherine Edney & Niek Stadhouders & Ijeoma Edoka & Iván Castilla-Rodríguez & Lidia García-Pérez & Renata Linertová & Cristina Valcárcel-Nazco & Jon, 2022. "Are Estimates of the Health Opportunity Cost Being Used to Draw Conclusions in Published Cost-Effectiveness Analyses? A Scoping Review in Four Countries," Applied Health Economics and Health Policy, Springer, vol. 20(3), pages 337-349, May.
  27. Eun-Young Bae & Hui Jeong Kim & Hye-Jae Lee & Junho Jang & Seung Min Lee & Yunkyung Jung & Nari Yoon & Tae Kyung Kim & Kookhee Kim & Bong-Min Yang, 2018. "Role of economic evidence in coverage decision-making in South Korea," PLOS ONE, Public Library of Science, vol. 13(10), pages 1-12, October.
  28. Jennifer Whitty & Sharyn Rundle-Thiele & Paul Scuffham, 2012. "Insights from triangulation of two purchase choice elicitation methods to predict social decision making in healthcare," Applied Health Economics and Health Policy, Springer, vol. 10(2), pages 113-126, March.
  29. Yong Yi Lee & Cathrine Mihalopoulos & Mary Lou Chatterton & Susan L Fletcher & Patty Chondros & Konstancja Densley & Elizabeth Murray & Christopher Dowrick & Amy Coe & Kelsey L Hegarty & Sandra K Davi, 2022. "Economic evaluation of the Target-D platform to match depression management to severity prognosis in primary care: A within-trial cost-utility analysis," PLOS ONE, Public Library of Science, vol. 17(5), pages 1-14, May.
IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.